Barclays lowered the firm’s price target on Exelixis to $24 from $25 and keeps an Overweight rating on the shares. The analyst says Q2 Cabozantinib sales beat consensus.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXEL: